Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RH125 in advanced solid tumors
NCT07182435Phase 1Not yet recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RH125 in solid tumor (2 arms), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 24 months and 3 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
RH125
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07182435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182435.